0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Gelesis Holdings
Its shares trade under the ticker GLSHQ. It has been listed since 7 July 2020. In the fiscal year to 31 December 2022, it reported revenue of $25.8m and a net loss of $57.1m. At that date it held total assets of $103.3m and shareholders' equity of −$25.1m.
Gelesis Holdings, Inc. operates as a biotechnology company. The company is headquartered in Boston, Massachusetts. The company went IPO on 2020-07-07. The firm focuses on advancing superabsorbent hydrogel therapeutics for chronic gastrointestinal (GI) diseases including excess weight, type two diabetes, Nonalcoholic Fatty Liver Disease (NAFLD)/ Nonalcoholic Steatohepatitis (NASH), functional constipation (FC), and inflammatory bowel disease. Its product, Plenity, is an orally administered capsule. Plenity is available by prescription via a telehealth consultation with a physician trained in weight management support, with free, unlimited follow-up visits as needed. Consumers can visit myplenity.com for online consultations. Its other pipeline candidate includes GS200 for weight loss in prediabetes and type two diabetes. The company is also developing GS300 for the treatment of NAFLD and NASH, and GS500 for the treatment of Functional Constipation (FC).
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 7 Jul 2020
- Employees
- 93
- Website
- capstarspac.com ↗
Leadership
Pay as last reported
- Mr. Yishai ZoharPresident, Chief Executive Officer, Director, Co-Inventor, since 2022$5.4m
- Mr. Elliot MaltzChief Financial Officer, Treasurer, Chief Compliance Officer, Corporate Secretary$2.5m
- Dr. David PassChief Operating Officer, Chief Commercial Officer$3.0m
- Dr. Alessandro SanninoCo-Inventor, Lead Project Scientist
- Ms. Alison BauerleinIndependent Director$202,646
- Ms. Kathryn CavanaughIndependent Director$187,780
- Mr. Clayton ChristopherIndependent Director$190,500
- Mr. Paul FonteyneIndependent Director$218,969
- Ms. Jane WildmanIndependent Director$197,203
- Ms. Katie SullivanInvestor Relations, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 21
- Environment
- 5
- Social
- 35
- Governance
- 23
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Gelesis Holdings focuses on superabsorbent hydrogel therapeutics for chronic GI diseases including weight management and diabetes.
- Plenity is available by prescription via telehealth consultation with physicians trained in weight management.
- The company has a pipeline of products including GS200, GS300, and GS500 targeting various gastrointestinal conditions.
Weaknesses
- Gelesis Holdings has only 93 employees, which may limit operational capacity.
- The company's IPO was on 7 July 2020, indicating a relatively recent market entry.
- Plenity requires a telehealth consultation for prescription, potentially limiting accessibility.
Opportunities
- The growing market for NAFLD/NASH treatments presents a significant opportunity for GS300.
- GS200 targets prediabetes and type two diabetes, aligning with rising global health concerns.
- The company can expand Plenity's availability through additional telehealth partnerships.
Threats
- The biotechnology sector faces intense competition from established pharmaceutical companies.
- Regulatory challenges may delay the approval of GS300 for NAFLD/NASH treatment.
- Plenity's reliance on telehealth consultations could be affected by changes in healthcare policies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.